These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1572 related articles for article (PubMed ID: 35874698)

  • 1. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
    Zhang P; Zhang Y; Ji N
    Front Immunol; 2022; 13():927132. PubMed ID: 35874698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma.
    Zhou S; Sun H; Choi SI; Yin J
    Front Biosci (Landmark Ed); 2023 Sep; 28(9):206. PubMed ID: 37796692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing CAR-T Therapy for Glioblastoma.
    Tang OY; Binder ZA; O'Rourke DM; Bagley SJ
    Mol Diagn Ther; 2023 Nov; 27(6):643-660. PubMed ID: 37700186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives.
    Montoya M; Gallus M; Phyu S; Haegelin J; de Groot J; Okada H
    Cells; 2024 Apr; 13(9):. PubMed ID: 38727262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?
    Drougkas K; Karampinos K; Karavolias I; Koumprentziotis IA; Ploumaki I; Triantafyllou E; Trontzas I; Kotteas E
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2709-2734. PubMed ID: 36564524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults.
    Talleur AC; Fabrizio VA; Aplenc R; Grupp SA; Mackall C; Majzner R; Nguyen R; Rouce R; Moskop A; McNerney KO
    Transplant Cell Ther; 2024 Jun; 30(6):565-579. PubMed ID: 38588880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
    Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
    Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR-T Cells Therapy in Glioblastoma: A Systematic Review on Molecular Targets and Treatment Strategies.
    Agosti E; Garaba A; Antonietti S; Ius T; Fontanella MM; Zeppieri M; Panciani PP
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.
    Yoo HJ; Harapan BN
    Immunol Res; 2021 Dec; 69(6):471-486. PubMed ID: 34554405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.
    Verma A; Rafiq S
    Cancer Treat Res; 2022; 183():161-184. PubMed ID: 35551659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future.
    Lin YJ; Mashouf LA; Lim M
    Front Immunol; 2022; 13():817296. PubMed ID: 35265074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
    Lindo L; Wilkinson LH; Hay KA
    Front Immunol; 2020; 11():618387. PubMed ID: 33643299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies.
    Liu Y; Peng C; Ahad F; Ali Zaidi SA; Muluh TA; Fu Q
    Recent Pat Anticancer Drug Discov; 2024; 19(5):557-572. PubMed ID: 38213150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR-T Therapies in Solid Tumors: Opportunities and Challenges.
    Guzman G; Reed MR; Bielamowicz K; Koss B; Rodriguez A
    Curr Oncol Rep; 2023 May; 25(5):479-489. PubMed ID: 36853475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem.
    Gatto L; Franceschi E; Di Nunno V; Maggio I; Lodi R; Brandes AA
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1333-1353. PubMed ID: 34734551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future.
    Li L; Zhu X; Qian Y; Yuan X; Ding Y; Hu D; He X; Wu Y
    Front Immunol; 2020; 11():594271. PubMed ID: 33224149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective approaches to enhancing CAR T cell therapy for glioblastoma.
    Choi SI; Yin J
    Front Immunol; 2022; 13():1008751. PubMed ID: 36275671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 79.